{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T07:49:51Z","timestamp":1794383391756,"version":"4.9.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004564","name":"Ministarstvo Prosvete, Nauke i Tehnolo\u0161kog Razvoja","doi-asserted-by":"publisher","award":["175035"],"award-info":[{"award-number":["175035"]}],"id":[{"id":"10.13039\/501100004564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.atherosclerosis.2018.11.020","type":"journal-article","created":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T16:19:54Z","timestamp":1541780394000},"page":"14-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Association between proprotein convertase subtilisin\/kexin 9 (PCSK9) and lipoprotein subclasses in children with type 1 diabetes mellitus: Effects of glycemic control"],"prefix":"10.1016","volume":"280","author":[{"given":"Dragana","family":"Bojanin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Vekic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Milenkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rade","family":"Vukovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Zeljkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Stefanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2835-1315","authenticated-orcid":false,"given":"Jelena","family":"Janac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmina","family":"Ivanisevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Mitrovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3929-4697","authenticated-orcid":false,"given":"Milica","family":"Miljkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesna","family":"Spasojevic-Kalimanovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2018.11.020_bib1","doi-asserted-by":"crossref","first-page":"218","DOI":"10.2337\/diacare.29.02.06.dc05-0724","article-title":"Spectrum and prevalence of atherogenic risk factors in 27,358 children, adolescents, and young adults with type 1 diabetes: cross-sectional data from the German diabetes documentation and quality management system (DPV)","volume":"29","author":"Schwab","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2018.11.020_bib2","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2337\/dc08-1775","article-title":"Lipid and lipoprotein profiles in youth with and without type 1 diabetes: the SEARCH for DIABETES in youth case-control study","volume":"32","author":"Guy","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2018.11.020_bib3","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.diabet.2009.04.004","article-title":"Lipid disorders in type 1 diabetes","volume":"35","author":"Verg\u00e8s","year":"2009","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.atherosclerosis.2018.11.020_bib4","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s00395-015-0463-z","article-title":"Molecular and cellular function of the proprotein convertase subtilisin\/kexin 9 (PCSK9)","volume":"110","author":"Schulz","year":"2015","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.11.020_bib5","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.clinbiochem.2014.03.022","article-title":"The effect of insulin on circulating PCSK9 in postmenopausal obese women","volume":"47","author":"Awan","year":"2014","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.atherosclerosis.2018.11.020_bib6","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1373\/clinchem.2009.126987","article-title":"Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents","volume":"55","author":"Baass","year":"2009","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2018.11.020_bib7","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/pedi.12490","article-title":"Obesity and type 2 diabetes are associated with elevated PCSK9 levels in young women","volume":"18","author":"Levenson","year":"2016","journal-title":"Pediatr. Diabetes"},{"key":"10.1016\/j.atherosclerosis.2018.11.020_bib8","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.2337\/dc16-2563","article-title":"PCSK9 is increased in youth with type 1 diabetes","volume":"40","author":"Levenson","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2018.11.020_bib9","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.numecd.2015.01.006","article-title":"Association of plasma small dense LDL cholesterol with PCSK9 levels in patients with angiographically proven coronary artery disease","volume":"25","author":"Zhang","year":"2015","journal-title":"Nutr. Metabol. Cardiovasc. Dis."},{"key":"10.1016\/j.atherosclerosis.2018.11.020_bib10","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12944-016-0339-8","article-title":"Correlation between serum levels of proprotein convertase subtilisin\/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease","volume":"15","author":"Nozue","year":"2016","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.atherosclerosis.2018.11.020_bib11","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.clinbiochem.2014.03.008","article-title":"Plasma proprotein convertase subtilisin-kexin type 9 is predominantly related to intermediate density lipoproteins","volume":"47","author":"Kwakernaak","year":"2014","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.atherosclerosis.2018.11.020_bib12","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1515\/jomb-2016-0019","article-title":"Serum sdLDL-C and cellular SREBP2-dependent cholesterol levels; is there a challenge on targeting PCSK9?","volume":"4","author":"Soltanmohammadi","year":"2016","journal-title":"J. Med. Biochem."},{"key":"10.1016\/j.atherosclerosis.2018.11.020_bib13","series-title":"The Good Clinical Practice National Guidelines on Diabetes Mellitus","author":"Ministry of Health of Republic Serbia","year":"2012"},{"key":"10.1016\/j.atherosclerosis.2018.11.020_bib14","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/pedi.12186","article-title":"Definition, epidemiology, and classification of diabetes in children and adolescents","volume":"15","author":"Craig","year":"2014","journal-title":"Pediatr. Diabetes"},{"key":"10.1016\/j.atherosclerosis.2018.11.020_bib15","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/pedi.12190","article-title":"Assessment and monitoring of glycemic control in children and adolescents with diabetes","volume":"15","author":"Rewers","year":"2014","journal-title":"Pediatr. Diabetes"},{"key":"10.1016\/j.atherosclerosis.2018.11.020_bib16","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/dme.12329","article-title":"Early elevation of albumin excretion rate is associated with poor gluten-free diet adherence in young people with coeliac disease and diabetes","volume":"31","author":"Pam-Shorth","year":"2014","journal-title":"Diabet. Med."},{"key":"10.1016\/j.atherosclerosis.2018.11.020_bib17","doi-asserted-by":"crossref","first-page":"626","DOI":"10.2337\/diabetes.49.4.626","article-title":"Can clinical factors estimate insulin resistance in type 1 diabetes?","volume":"49","author":"Williams","year":"2000","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosis.2018.11.020_bib18","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.clinbiochem.2006.11.013","article-title":"LDL and HDL subclasses and their relationship with Framingham risk score in middle-aged Serbian population","volume":"40","author":"Vekic","year":"2007","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.atherosclerosis.2018.11.020_bib19","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.atherosclerosis.2009.11.040","article-title":"LDL and HDL subclasses in acute ischemic stroke: prediction of risk and short-term mortality","volume":"210","author":"Zeljkovic","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.11.020_bib20","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.tem.2018.03.013","article-title":"Beyond LDL: what role for PCSK9 in triglyceride-rich lipoprotein metabolism?","volume":"29","author":"Dijk","year":"2018","journal-title":"Trends Endocrinol. Metabol."},{"key":"10.1016\/j.atherosclerosis.2018.11.020_bib21","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1161\/ATVBAHA.112.250043","article-title":"Proprotein convertase subtilisin\/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor","volume":"32","author":"Sun","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2018.11.020_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/qjmed\/hci154","article-title":"Low-density lipoprotein size and cardiovascular risk assessment","volume":"99","author":"Rizzo","year":"2006","journal-title":"QJM"},{"key":"10.1016\/j.atherosclerosis.2018.11.020_bib23","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1007\/s00125-015-3525-8","article-title":"Pathophysiology of diabetes dyslipidaemia: where are we?","volume":"58","author":"Verg\u00e8s","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.atherosclerosis.2018.11.020_bib24","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/1476-511X-13-188","article-title":"Relation of plasma PCSK9 levels to lipoprotein subfractions in patients with stable coronary artery disease","volume":"13","author":"Xu","year":"2014","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.atherosclerosis.2018.11.020_bib25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1074248417724868","article-title":"Effects of PCSK9 inhibitors on other than low density lipoprotein cholesterol lipid variables","volume":"23","author":"Filippatos","year":"2018","journal-title":"J. Cardiovasc. Pharmacol. Therapeut."},{"key":"10.1016\/j.atherosclerosis.2018.11.020_bib26","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/dom.12819","article-title":"Glycaemic control influences the relationship between plasma PCSK9 and LDL cholesterol in type 1 diabetes","volume":"19","author":"Laugier-Robiolle","year":"2017","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.atherosclerosis.2018.11.020_bib27","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1194\/jlr.P060657","article-title":"Associations between intensive diabetes therapy and NMR-determined lipoprotein subclass profiles in type 1 diabetes","volume":"57","author":"Zhang","year":"2016","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2018.11.020_bib28","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.atherosclerosis.2014.12.017","article-title":"On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects","volume":"238","author":"Tavori","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.11.020_bib29","doi-asserted-by":"crossref","first-page":"8279","DOI":"10.1074\/jbc.M112.421370","article-title":"Low density lipoprotein binds to proprotein convertase subtilisin\/kexin type 9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation","volume":"288","author":"Koshenko","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2018.11.020_bib30","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00395-017-0619-0","article-title":"Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease","volume":"112","author":"Glerup","year":"2017","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.11.020_bib31","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/cvr\/cvw194","article-title":"Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering","volume":"112","author":"Norata","year":"2016","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.atherosclerosis.2018.11.020_bib32","doi-asserted-by":"crossref","first-page":"462","DOI":"10.5551\/jat.RV17003","article-title":"PCSK9 and atherosclerosis - lipids and beyond","volume":"24","author":"Shapiro","year":"2017","journal-title":"J. Atherosclerosis Thromb."},{"key":"10.1016\/j.atherosclerosis.2018.11.020_bib33","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1161\/ATVBAHA.110.214130","article-title":"Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans, Arterioscler","volume":"30","author":"Persson","year":"2010","journal-title":"Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2018.11.020_bib34","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.abb.2007.11.009","article-title":"Diabetes alters LDL receptor and PCSK9 expression in rat liver","volume":"470","author":"Niesen","year":"2008","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.atherosclerosis.2018.11.020_bib35","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1161\/ATVBAHA.115.305688","article-title":"The role of insulin in the regulation of proprotein convertase subtilisin\/kexin type 9, Arterioscler","volume":"35","author":"Miao","year":"2015","journal-title":"Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2018.11.020_bib36","doi-asserted-by":"crossref","first-page":"6211","DOI":"10.1074\/jbc.M508582200","article-title":"Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element- binding protein 1c","volume":"281","author":"Costet","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2018.11.020_bib37","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.2337\/dc06-2053","volume":"30","author":"Pambianco","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2018.11.020_bib38","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915018314758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915018314758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:37:29Z","timestamp":1758155849000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915018314758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":38,"alternative-id":["S0021915018314758"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.11.020","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between proprotein convertase subtilisin\/kexin 9 (PCSK9) and lipoprotein subclasses in children with type 1 diabetes mellitus: Effects of glycemic control","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.11.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}